BPGbio, Inc.

?? BPGbio, Inc. presents the four step NAi process. 2?? Step 2: Multiomics Analysis Multiomics Analysis is where our scientists funnel our comprehensive multiomics data into causal AI and explainable networks for high-confidence targets and biomarkers. Causation, not correlation, gets to the root cause of the disease, which in turn, not only improves clinical outcomes, but better treats the patient, not just the disease. The power of NAi, our causal AI-driven Interrogative Biology? platform. ?? BPGbio, Inc. is ready for #collaboration and #partnership pipeline engagement with pharma partners. ?? Visit www.bpgbio.com to learn more. #NAiInterrogativeBiology #AI #biopharma #biotech #clinicaltrials #research #causalAI #AIPlatform #Drugdiscovery #GenerativeAI

I had the honor of spending a few days before #RareDiseaseDay discussing and learning more about potential therapeutics for Huntington's disease, a rare genetic neurodegenerative disease, at the 20th Annual CHDI Foundation Conference. Thanks to everyone who stopped by my poster to learn more about the exciting research happening at BPGbio, Inc. in hopes to one day treat such a terrible disorder. Happy Rare Disease Day! Just because it is rare, does not mean it should be forgotten.

BPGbio, Inc.'s scientific poster from the 2025 CHDI Foundation 20th Annual Huntington's Disease Therapeutics Conference is now available for viewing download! ?? Huntington’s disease (HD) is a uniformly fatal, autosomal dominant, neurodegenerative disorder caused by a triplet repeat expansion of glutamine (polyQ) codons (CAG) in the N-terminal coding exon (exon 1) of the Huntingtin (Htt) gene. The expression of mutant Htt (muHtt) is associated with the accumulation of intracellular aggregates containing the mutant protein and leads to the degeneration of the basal ganglia with progressive loss of striatal medium spiny neurons as well as the loss of cortical and other neurons. The poster includes details showcasing how BPGbio, Inc.'s NAi Interrogative Biology platform discovered targets of Huntington's disease. The full poster presented at CHDI2025 by Devyn Oliver, Ph.D., Neurology Scientist at BPGbio, Inc., "Disruption of mutant, polyQ expanded huntingtin aggregation by modulation of UBE2K, a novel ubiquitin-proteasome drug target" can be downloaded on the BPGbio.com website here: https://lnkd.in/gQqnQtew #CHDI2025 #huntingtonsdisease #E2notE3 #NAiInterrogativeBiology #biomarkers #drugtargets #drugdiscovery #AI #scientificposters

???????????????????? ???????????????????????? ???? ???????? ?????????????????? ???????????? ???? ?????????? $????.?? ???? ???? ???????? The integration of Artificial Intelligence (AI) in drug discovery is revolutionizing pharmaceutical research, paving the way for faster, more efficient, and cost-effective drug development. With the AI-driven drug discovery market projected to reach $15.5 billion by 2032, the industry is witnessing a paradigm shift. ?????? ???????? ???????????? ????????????@ https://lnkd.in/dH8vZdkH ?????????????????????????? ???????????????????????? ?????????????? ????????????: AI and machine learning are playing a pivotal role in: ? Target Identification & Validation – AI models analyze complex biological data to pinpoint promising drug targets. ? Molecular Design & Optimization – Generative AI accelerates the creation of novel compounds with optimized properties. ? Predictive Analytics for Clinical Trials – AI helps assess drug efficacy and toxicity, reducing failure rates. ? Automation & High-Throughput Screening – Robotics and AI-driven labs accelerate compound testing. ???????????? ???????????????? & ???????????????? ??????????????: ?? Rising R&D Costs & Drug Failures – AI offers a solution by reducing time-to-market and increasing success rates. ?? Pharma & Biotech Investments – Companies are actively partnering with AI firms to enhance drug development pipelines. ?? Regulatory & Ethical Considerations – AI-driven solutions must navigate evolving regulatory landscapes for adoption. ?????? ??????????????: IBM, Exscientia, Insilico Medicine, Aitia , Google DeepMind , BenevolentAI, BioSymetrics, Incedo Inc.., BPGbio, Inc. , Atomwise, insitro, CYCLICA, NVIDIA, Schr?dinger, Microsoft, Illumina, Incedo Inc.., NuMedii, XtalPi Inc., iktos, Tempus, Deep Genomics, Verge Genomics, BenchSci, Valo Health, BPGbio, Inc., Merck KGaA, Darmstadt, Germany, IQVIA, IGE/Affinity Media (acq. Tencent Holdings Ltd.), Predictive Oncology, CytoReason, OWKIN, Incedo Inc.., Cloud Pharmaceuticals, Inc., Evaxion Biotech A/S, Standigm, BioAge Labs, Envisagenics, AbCellera, Centella. ???????????? ??????????????: Personalized Medicine – AI will enable precision therapies tailored to individual patient genetics. Rare & Complex Disease Research – AI will unlock new treatments for diseases previously deemed untreatable. AI-Powered Drug Repurposing – Existing drugs will be optimized for new therapeutic applications. #AI #DrugDiscovery #PharmaTech #ArtificialIntelligence #MachineLearning #Biotech #Lifesciences #DigitalHealth #Bioinformatics #DeepLearning #ClinicalTrials #DrugDevelopment #PrecisionMedicine #HealthcareInnovation #BigData #Biopharma #HealthTech #MedicalResearch #Innovation #AIinHealthcare #FutureOfMedicine

Even after remarkable advances in cardiovascular therapy over the last few decades, CVD remains a huge unmet need. An area with paucity of advancement is targeting inflammation risk in atherosclerosis. At BPGbio, Inc. our innovative NAi platform has identified a novel first in class oral anti-inflammatory therapy to target residual risk in atherosclerotic cardiovascular disease. It has been shown that targeting inflammation can further reduce ASCVD risk by ~30% over cholesterol lowering. We are excited to move into phase 1 studies before the end of the year.

?? Join BPGbio, Inc. this Rare Disease Day in doing our part to support our friends, neighbors and colleagues who live with a rare disease. It's more than you realize! ?? There are many rare diseases. At BPGbio, Inc. we are continuously searching for new treatments and solutions for them. Just a few statistics to showcase just how common rare diseases actually are (and, the affects they may have): - 30 Million American's live with a rare disease. 1 in 10! - Any disease affecting few than 200,000 people in the U.S. is considered rare. - Currently, there are more than 10,000 rare diseases identified. - All pediatric cancers are considered rare. - Many rare diseases may result in the premature death of infants or can be fatal in early childhood. Chances are someone close to you has, or is affected by, a rare disease. Please feel free to share your stories in the comments. ?? ?? Please visit the Rare Disease Day (global) website at https://lnkd.in/gk6hbAF or the National Organization for Rare Disorders (North America) website at https://lnkd.in/e2nh5pd for more information and ways you can give support. ?? For more information about how BPGbio, Inc. is working to find treatments for rare disease, please visit our website at www.bpgbio.com #RareDiseaseDay #raredisease #biopharma #mitochondrialdisease #raredisorders #pediatriccancer #showyourstripes

In recognition of Rare Disease Day tomorrow, Feb. 28th, we'd like to offer this video bringing awareness to how primary CoQ10 deficiency symptoms can manifest. ?? Those suffering from primary CoQ10 deficiency may experience many neurological disorders including progressive cerebellar ataxia, mitochondrial myopathy, encephalomyopathy, intellectual disability, hypogonadism, seizures, steroid resistant nephrotic syndrome, and stroke-like episodes.1,2 The patient in the video presented here is suffering from progressive cerebellar ataxia and dystonia. The video is part of a paper published in Movement Disorders Clinical Practice (Official Journal of the International Parkinson and Movement Disorder Society) by Divya M. Radhakrishnan, MD, DM, et al. From the paper: "A 29-year-old male, born out of non-consanguineous marriage, presented with history of abnormal posturing and tremors of the neck and upper limbs since 10 years of age. The symptoms developed a week after febrile illness and he had a single episode of seizure at that point. He noticed trembling in his voice from 20 years of age and unsteadiness of gait since 25 years of age, with clumsiness of hands. Symptoms were slowly progressive, with temporary worsening during febrile illness and after heavy exertion. There was no history of rest tremor, slowness of activi- ties, cognitive impairment or weakness of limbs. His birth and development were normal and family history was unremarkable. He received a trial of levodopa, but had no benefit." ?? The full paper can be viewed here (possible paywall): https://lnkd.in/gJumrDJy Rare disease, such as primary CoQ10 deficiency, is all around us with approximately 5% of the population suffering from one. They could be your friends, family, neighbors or colleagues. Please consider supporting rare disease research, treatments, and supportive services this Rare Disease Day. ?? For more information about BPGbio, Inc., please visit our website at www.bpgbio.com Thank you. #raredisease #primarycoq10deficiency #rarediseaseday #cerebellarataxia #dsytonia #biopharma #research #mitochondrialdisease #mitochondrialmedicine #coq10 #movementdisorders 1. Emmanuele V, Lopez LC, Berardo A, et al. Heterogeneity of coenzyme Q10 deficiency: patient study and literature review. Arch Neurol 2012; 69(8):978–983. 2. Quinzii CM, Hirano M. Primary and secondary CoQ(10) deficiencies in humans. Biofactors 2011;37(5):361–365.

Join Devyn Oliver, Ph.D. and our team today at the 20th Annual Huntington's Disease Therapeutics Conference in Palm Springs, CA and hear about how we discovered our novel ubiquitin-proteasome UBE2K target through the NAi Interrogative Biology platform, and how UBE2K discharge inhibitor, BPG-0812 demonstrates potential to reduce toxic protein aggregates in Huntington's Disease. More about our NAi platform: https://lnkd.in/gvTXPEEf Our E2 program: https://lnkd.in/ghG8APdR #huntingtonsdisease #neurology #raredisease #AIplatform #Palmsprings #science #therapeutics #pipeline #E2notE3 #presentation

BPGbio's NAi Interrogative Biology AI Platform explained, step by step. Unlike?generative AI, which is based on pre-existing data of unknown quality, limiting its ability to de-risk assets and often pursuing dead-end leads,?NAi starts with our proprietary biobank which houses over a hundred thousand patients’ samples?of?tissue, cells, and patient biofluids, from healthy, diseased, and recovery states, as well as their health records and electronic information. Our expert scientists conduct comprehensive multiomics analysis on these samples, going way beyond DNA and RNA, funneling the data into causal AI and explainable networks for high-confidence targets and biomarkers. Read more about our platform: https://lnkd.in/gvTXPEEf For #collaboration and #partnership, email [email protected] #NAiInterrogativeBiology #AI #biopharma #biotech #clinicaltrials #multiomics #research?#biobank #biologyfirst?#AIplatform

Yesterday, our?Chief Medical Officer, Vijay Modur, MD, PhD, shared insights on?BPGbio, Inc.’s GBM clinical program?at the?6th Glioblastoma Drug Development Summit?in Boston. ?? During his presentation, Dr. Modur showcased compelling?in vitro data?and?patient scans, highlighting the potential of?BPM31510?as a treatment for?glioblastoma multiforme (#GBM)—one of the most aggressive and treatment-resistant brain cancers. BPGbio, Inc.’s BPM31510 is an ubidecarenone (ubiquinone; Coenzyme Q10) containing nanodispersion with anti-cancer effects mediated by molecular mechanisms in mitochondria that trigger the process of regulated cell death. BPGbio, Inc.’s BPM31510 was found to be active in human GBM cell models in vitro and in an orthotopic rat glioma model in vivo. Using an orthotopic glioblastoma animal model, treatment with BPGbio, Inc.’s BPM31510 resulted in significantly prolonged survival, with 29% of animals living up to 50 days while all non-treated animals died within 16 days (ref). Furthermore, in vitro treatment of glioma cells and non-tumor cell co-cultures with BPGbio, Inc.’s BPM31510 differentially and rapidly raised intramitochondrial superoxide levels in glioma cells relative to non-tumor cells to induce cell death. ?? For more information on our GBM trial:?https://lnkd.in/gpuKExVX #NAiInterrogativeBiology #AI #biopharma #braincancer #cancersurvival #clinicaltrial #mitochondrialmedicine #GDDS2025 #BostonConferences #CoQ10